Lung cancer is also known as Lung Carcinoma which is usually a malignant tumor that is caused by the unnecessary growth of cells in a particular region or area. This growth can spread beyond the lung process of metastasis into the nearby tissue or organs which can cause damages to the organs and makes them unable to work. These cancers may spread or be consigned to a particular area based on the type of cancer it is. There are two main types of cancer, they are small-cell lung carcinoma and non-small-cell lung carcinoma. Some of the symptoms of this cancer are weight loss, shortness of breath, and chest pain.
The Newly Approved Drug Helps To Control And Remove Lung Cancer
As per the recent reports, a newly approved lung cancer drug shows promise in improving survival in patients whose tumors carry the common and tough-to-treat genetic mutation. The drugs named Sotorasib and Lumarkas were approved by the United Nations Food and Drug Administration for those people who have had non-small-cell lung carcinoma with tumors that express the G12C mutation in the KRAS gene, and who have undergone at least one previous lung cancer treatment.
As per the reports of the noted oncologist, Dr. Kevin Sullivan non-small-cell lung carcinoma is the most common type of lung cancer and about 80% of the lung tumors are non-small-cell lung carcinoma and mutations like the G12C KRAS gene mutation can be particularly the drivers for cancer’s ability to grow, invade and spread, the doctor also treats the patients at the Northwell Health Cancer Institute in Lake Success, New York.
Sotorasib is designed to block the effects of the G12C KRAS gene mutation, where it is found that about 13% of patients with lung adenocarcinoma, which is a common type of non-small-cell lung carcinoma. He also mentioned that in the effective treatments the KRAS mutation was not felt to be actionable. As per the news report, the new international phase 2 clinical trials were funded by the drug maker, Amgen.
The researchers also assessed the effectiveness of the sotorasib in 126 patients who had tumors with the G12C KRAS gene mutation. It was found that the tumor shrinkage of 82% of the people, and the tumors by at least 30% in about 37% of the patients, the researchers reported. In comparison, the patient response rates to current standard therapy range between 6% to 20% as per the author reports. The reports also suggest that the partial response to the drug, meaning that the tumor shrank substantially, and its growth was controlled for some time and it was seen in 34% of the patients, while 3% of them experienced a complete response, which means that they were left with no evidence of cancer.
Also, for the tumors that shrank the reduction was about 60% on average. As per the author reports, the effect of the drug lasted an average of 11 months with progression-free survival of nearly seven months, which is nothing but the tumors did not grow for this period. And the average progression-free survival is two to four months with standard therapy. As per the recent meeting which was held by the American Society of Clinical Oncology that happened on June 4, the average survival of the patients after this drug was 12.5 months and these findings were published simultaneously published by the New England Journal of Medicine.
Now coming to the side effects of this new drug, about 7% of patients discontinued this new drug treatment because of the side effects but none of them are life-threatening as per the study. About 22% of the patients had severe side effects which led them to a complete reduction of one of the doses and almost 70% of the patients had some type of side effects and the most common type of symptoms are diarrhea, fatigue, nausea, and increased liver enzyme levels, which later indicated the liver damages in the later stages.